These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

931 related articles for article (PubMed ID: 29936771)

  • 1. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    Yin X; Chen H; Sun Y; Xiao L; Lu H; Guo W; Yang H; Zhou J; Fan K; Liang W
    Sci Rep; 2024 May; 14(1):11984. PubMed ID: 38796631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
    Toh E; Wilson J; Sebag-Montefiore D; Botterill I
    Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
    Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
    J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
    Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
    Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.
    Wang D; Guo D; Li A; Wang P; Teng F; Yu J
    Future Oncol; 2020 Mar; 16(9):439-449. PubMed ID: 32141321
    [No Abstract]   [Full Text] [Related]  

  • 15. [Impact of neutrophil-to-lymphocyte ratio on the prognosis of patients with locally advanced colorectal cancer].
    Jiang H; Wang H; Li A; Tang E; Chen Y; Wang A; Deng X; Lin M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):550-554. PubMed ID: 28534334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].
    Wang X; Li K
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):298-302. PubMed ID: 24989918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.
    Zeng YC; Chi F; Xing R; Xue M; Wu LN; Tang MY; Wu R
    Jpn J Clin Oncol; 2016 Feb; 46(2):126-31. PubMed ID: 26611205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.